Generate:Biomedicines

We are excited to announce Wiskensley Pierre (Wiz) as the recipient of our #FiercelyUnited Mindset Award! This award recognizes those who focus on collective achievement, trust, and accountability - demonstrating the true spirit of teamwork within #TeamGenerate. Wiz exemplifies what it means to be fiercely united by always supporting diverse perspectives and fostering a cohesive team environment. This summer, Wiz also completed a master’s in cybersecurity, reinforcing our defense against these threats and ensuring our collective security. Want to join a team that values collaboration and innovation? Explore opportunities with us: https://lnkd.in/gKaKkEGJ #ProgrammingBiology | #NowWeCan

Why would a seasoned chief legal officer with 24 years of experience pivot to a startup? Our Chief Legal Officer and General Counsel, Sean Martin, explores this question in a recent Financial Times article by Jane Croft.    For Sean, joining #TeamGenerate wasn’t just a career move—it was about being at the forefront of the #GenerativeBiology revolution. He was drawn by the opportunity to collaborate with some of the brightest minds aimed at transforming human health. Describing our vibrant atmosphere, Sean says, “There are a lot of younger scientists who have taken this as their first job after their PhDs, and there is a buzz around the place, which is exciting, with new people joining every week.” Explore the full article👇    https://lnkd.in/gHPcURkM  #TeamGenerate | #AudatiouslyAmbitious

Last week, Jason Silvers, our CFO, was recognized at the Boston Business Journal's 2024 CFO of the Year awards. This accolade honors chief financial officers who have significantly impacted their organizations and the broader economy. In an interview with the Boston Business Journal, Jason discusses his career shifts from medicine to law to finance. He highlights how these experiences have equipped him to lead our financial strategies effectively, particularly in challenging market conditions. The interview offers a glimpse into his professional perspective and decision-making process. Don't miss the full interview 👇 #TeamGenerate | #AudaciouslyAmbitious 

Could biomarkers be the key to unlocking the future of drug discovery? Our EVP and Head of R&D, Alexandra Snyder, MD, delves into the potential for biomarkers to help the field understand resistance to immunotherapy in her latest publication for the Journal for ImmunoTherapy of Cancer. The article examines the current state of PD-(L)1 therapies and highlights how innovations in biomarker strategies can help understand resistance to checkpoint blockade therapies, with the hope of identifying approaches to deliver more effective treatments to those most in need. Explore how these advancements are set to revolutionize patient care. Read the full article here: https://lnkd.in/e4zsfh4H #PatientFirst | #UnapologeticallyScientific 

Curious about how #AI is shaping the future of drug discovery? Don’t miss our CEO Michael Nally’s interview with Brad Loncar on BiotechTV at the AI x Bio Summit at the NYSE.    Mike shares exciting updates on our clinical programs, including our COVID-19 antibody and anti-TSLP molecule. Discover how we’re leveraging AI to build de novo proteins and reach historically undruggable targets. “By programming biology, we’re transforming drug discovery and creating better medicines faster." Learn more about the future of biotech in this compelling conversation.     Check out the full interview:    https://lnkd.in/gPFP2yEK    #ProteinEngineering | #GenerativeAI 

In 2024, women make up only 28.2% of the STEM workforce, with their representation in leadership roles even more staggering, with just 11% holding C-suite positions. These insights, from the 2024 Global Gender Gap Report by the World Economic Forum, highlight the crucial need for mentorship and support in advancing women’s careers. Leaders like our Chief Technical Operations Officer, Lisa Wyman, are essential in driving this change. Leadership isn’t just a title; it’s a journey. Lisa emphasizes the importance of authentic leadership, where nurturing potential and fostering innovation take center stage. She highlights the essential skills like conflict resolution, delegation, driving team results, and collaboration. Lisa's commitment to leadership and mentorship inspire us all. What qualities do you believe define a great leader? #WomenInSTEM | #FiercelyUnited | #TeamGenerate

Scientific discovery doesn’t happen in a silo. It requires industry-wide collaboration, bringing the brightest minds together around the latest technology that’s shaping the future of drug discovery and development.    With this spirit of partnership in mind, we were honored to welcome Dan Shine, Senior Vice President and President of the Analytical Instrument Group at Thermo Fisher Scientific, to our #CryoEM lab in Andover, Massachusetts. Alongside Claudio Morales Perez, Patricia Feliciano, Edward Brignole, and Adam Root, the day featured a tour of our facility.     Want to join our cutting-edge CryoEM team? We’re currently seeking a Software Engineer III, Computational Structure Determination. Learn more here: https://lnkd.in/eJbVHqXb    #UnapologeticallyScientific | #GenerativeAI 

Nearly six years ago, we joined the #FlagshipFounded ecosystem, paving the way for Flagship Pioneering’s #AI portfolio and kickstarting the #GenerativeBiology revolution.    In a recent article for Genetic Engineering & Biotechnology News, senior business editor Alex Philippidis discusses Flagship’s latest fundraising round and what it means for startups in the life sciences, sustainability and AI space.     Check it out here: https://lnkd.in/evnbfpX9    #ProteinEngineering I #MachineLearning 

What does it take to build an AI-driven biotech in 2024? Our CEO Michael Nally will share his insight into this very topic as part of a panel discussion at Decoding Bio’s second annual AI x Bio Summit at the NYSE on July 25.    Convening industry leaders working at the intersection of computation and life sciences, this panel will explore company building strategies, emerging technologies, stakeholder engagement, and more.     Mike will be joined by panelists Nabiha Saklayen of Cellino and Sajith Wickramasekara of Benchling, with Bigyan Bista of Enveda Biosciences moderating the discussion.    #GenerativeAI | #UnapologeticallyScientific

What can’t AI do? Kyle LaHucik at Endpoints News sets out to answer this by exploring how #AI is revolutionizing biotech with insights from Noubar Afeyan, CEO and founder of Flagship Pioneering and our chairman and co-founder.    “Multiple Flagship companies are doing work in AI, most notably with Generate:Biomedicines, which has raised more than $700 million to create new proteins using artificial intelligence. It has a broad pipeline across immunology, infectious disease, and oncology,” Afeyan highlighted.    #TeamGenerate is harnessing AI to program biology, transforming how medicines are created. Together, we’re targeting humanity’s most intractable diseases with unprecedented precision and speed.    Discover more about how AI is driving the future of biotech. https://lnkd.in/dx759Vt9     #GenerativeBiology | #NowWeCan | #FlagshipFounded